Skip to main content
. 2013 Jan 29;80(5):453–457. doi: 10.1212/WNL.0b013e31827f0f42

Figure 3. Immunologic studies comparing ZAP10 with other daclizumab-treated patients with multiple sclerosis.

Figure 3

(A, B) Immunologic studies were performed at pretreatment baseline and after 6.5 months of daclizumab therapy, as reported perviously.2,10 Data from patient ZAP10 are highlighted as thicker black lines in each panel.